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Abstract
Study Objective—Cervical cancer morbidity and mortality are pressing public health issues 
impacting women in Haiti. To inform efforts to develop a human papillomavirus (HPV) 
vaccination program in Haiti, we sought to understand HPV awareness and willingness to get HPV 
vaccination in Haiti.
Design, Setting, Participants—We interviewed a convenience sample of 475 women and men 
in two clinical settings in Port-au-Prince and Léogâne, Haiti between April and July 2014.
Main Outcome measures—HPV awareness and willingness to get HPV vaccine for daughters.
Results—Few (27%) participants had heard of HPV. Awareness of HPV was higher among 
respondents with a previous sexually transmitted infection (STI) as compared to those without a 
previous STI (OR=2.38, 95% CI: 1.10–5.13). Adults who had heard of genital warts were also 
more likely to be aware of HPV compared to those who had not (OR=4.37, 95% CI: 2.59–7.38). 
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Only 10% of parents had previously heard of HPV vaccine; however, after researchers explained 
the purpose of the vaccine, nearly all (96%) said they would be willing to get HPV vaccine for 
their daughters if it were available.
Conclusions—Despite low awareness of HPV in Haiti, interest in HPV vaccination was nearly 
universal in our study of healthcare-seeking adults. This high acceptability suggests that HPV 
vaccination programs instituted in Haiti would be well received.
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Introduction
Cervical cancer is the leading cause of cancer deaths among women in Haiti.1 Chronic 
infection with oncogenic types of human papillomavirus (HPV) causes cervical cancer and 
other cancers.2 Incident cervical cancer affects 23.2 per 100,000 Haitian women and claims 
the lives of 18.3 per 100,000 women annually.1 Corresponding rates for cervical cancer 
morbidity and mortality in the United States (U.S.) are much lower at 7.7 and 2.3 per 
100,000 respectively.3 These data portray an alarming public health crisis in Haiti that is 
largely preventable.
Cervical cancer screening is effective at preventing the disease, and indeed widespread 
screening is why cervical cancer rates in the U.S. have dropped by three quarters since its 
introduction.4 However, cervical cancer screening requires routine application, an 
infrastructure for follow-up and potential treatment of screening-identified abnormalities, 
which is unrealistic in many low-resource and rural settings. HPV vaccination offers an 
important alternative for cervical cancer prevention.5 The recently approved 9-valent HPV 
vaccine may prevent 90% of cervical cancers.6 HPV vaccine will be increasingly realistic in 
developing country settings like Haiti, as the vaccine becomes available at low or no cost 
through donations mainly from non-governmental organization-sponsored vaccination 
programs like the Gavi Alliance ‒a global coalition of public and private sector vaccine 
partners,7 and as two-dose series replace the more costly and resource intensive three-dose 
series.8
As immunization programs develop that can make HPV vaccine available in Haiti, more 
research is needed to assess HPV awareness and how receptive Haitians are likely to be 
towards the vaccine. To date, no study has assessed HPV awareness among Haitians, and 
data on HPV vaccine acceptability in this population is limited.9 Much of the research has 
been conducted with Haitian immigrants in the U.S. Studies have shown that Haitian 
immigrants have varying levels of HPV and HPV vaccine awareness.10–12 HPV awareness is 
a necessary antecedent of behavior change,13–15 according to several leading stage theories 
of health behavior.16–18 Given the dearth of information on HPV awareness in Haiti, we 
sought to examine levels of HPV awareness and predictors of HPV awareness among 
healthcare-seeking adults in Port-au-Prince and Léogâne, Haiti. We hypothesized that adults 
with previous sexually transmitted infections (STIs) would be more likely to be aware of 
HPV because of their subsequent medical care and related information seeking. We also 
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hypothesized that adults with higher socioeconomic status would be more likely to be aware 
of HPV because they have better resources to access healthcare services and information.
Materials and Methods
Participants and Procedures
Between April and July 2014, we recruited adults seeking healthcare services in two clinics 
in Haiti. The first was a women’s health clinic located in the Terre Noire district ‒a 
neighborhood of about 120,000 people located in Port-au-Prince, the capital of Haiti. This 
clinic provides routine clinical care including cervical cancer screening. The second clinic 
was located in the Léogâne Commune, one of the 140 communes of Haiti, located 22 miles 
west of Port-au-Prince with a population of 90,000 residents. The Léogâne clinic provides 
general medicine services to both men and women.
Procedures
A team of Duke University undergraduate students and local Haitian translators conducted 
the interviews. Interviewers received training on survey administration at Duke University as 
part of their field research project. Study participants were consented orally through a 
Haitian Creole translator. This method of consent was used due to the low rate of literacy 
among the Haitian population. At the interviewer’s direction, the translator read the consent 
form in Haitian Creole to determine intention to participate. Afterwards, participants signed 
their name or mark to confirm consent or agreed for a designee to sign on their behalf. 
Patients were surveyed in private rooms by the interviewer(s) and one translator. The 
translator read the survey questions in Haitian Creole while the interviewer followed along 
with the English version. After each response, the translator orally translated the 
participant’s response to English which was promptly hand-written on the English version of 
the survey by the interviewer. Participants received no monetary incentive to participate in 
the study. Institutional review boards at Duke University (Durham, NC) and Misyon Sante 
Fanme Ayisyen (Port-au-Prince, Haiti) approved the study protocol.
Measures
The survey was adapted from a questionnaire previously used by one of the authors (NB) to 
explore knowledge about HPV and cervical cancer and attitudes about HPV vaccination in 
Botswana.19 The original questionnaire was translated into Haitian Creole by an 
independent contractor, CreoleTrans, and was slightly modified by on-site clinical staff from 
the Terre Noire clinic for clarity of the content and literacy of the clinics’ population. The 
final version of the survey appears in the appendix.
The main outcome measure was awareness of HPV, assessed by a question that asked 
participants whether they have ever heard about HPV. The response options were “yes” or 
“no.” The survey then provided brief information about HPV, for example, “HPV (human 
papillomavirus) is a common sexually transmitted infection that sometimes leads to genital 
warts and cervical cancer” and “HPV is different from HIV.” The survey also asked 
participants who had daughters to rate their perceived likelihood of getting infected with 
HPV and the perceived threat of such an infection. The response options were “no 
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chance”/”no threat,” “low,” “moderate,” or “high.” The survey then asked respondents to list 
up to 3 reasons why getting the HPV vaccine for their daughters might be difficult. 
Instructions stated that respondents with daughters outside the HPV vaccine age range 
should answer these questions as if they were age-eligible.
The survey also asked parents whether they had ever heard of HPV vaccine, willingness to 
get the vaccine for their daughters, who they would consult in the decision to vaccinate their 
daughters, most common place they would take their daughters to get HPV vaccine, and how 
much they would be willing to pay for HPV vaccine. The survey assessed the following 
demographic characteristics and personal health variables: sex, age, marital status, 
education, employment status, religious background, children’s sex and gender (if any), 
history of STIs, contraceptive use, and awareness of genital warts.
Data Analysis
We used bivariate logistic regression models to examine correlates of HPV awareness. We 
then entered statistically significant (p<0.05) covariates in a multivariable logistic regression 
model using a forward stepwise procedure. Analyses were conducted using Stata version 14 
(College Station, TX). All statistical tests were two-tailed, using an alpha of 0.05. With 
regard to the open-ended question about potential barriers to HPV vaccination, two authors 
(MG, WC) independently coded responses and resolved any discrepancies through 
discussions.
Results
Most (86%) of the 475 study participants were women (Table 1). The majority of 
respondents were between the ages of 18 and 39 years (58%), were married or lived with a 
partner (57%), had more than primary education (65%), and were currently employed 
(76%). Of the 250 respondents who had daughters, 147 (31% of study sample) had at least 
one daughter who was between ages 11 and 26, the age range recommended in the U.S. to 
receive routine or catch-up HPV vaccination (5). Ten percent of respondents reported a 
history of STIs. The majority of survey participants did not use any methods of 
contraception or were unaware of the method their partner regularly used (79%) and had not 
heard of genital warts (75%). Participants seen at the Léogâne clinic and Terre Noire clinic 
differed on several demographic characteristics (Table 1).
HPV awareness
Twenty-seven percent of participants were aware of HPV at the time of the survey. 
Respondents who previously had a STI were over twice as likely to be aware of HPV as 
compared to those with no previous STI (OR = 2.38, 95% CI: 1.10–5.13) in multivariable 
analysis (Table 2). Adults who had heard of genital warts were also more likely to be aware 
of HPV than those who were not aware of genital warts (OR = 4.37, 95% CI: 2.59–7.38). In 
bivariate but not multivariable analyses, HPV awareness was associated (p<.05) with female 
sex, older age, current employment, Christian Protestant religion, and having a daughter in 
recommended age range for HPV vaccination.
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Of the 250 parents, one-third (32%) thought their daughters had a moderate to high chance 
of getting HPV infection and one-fourth (27%) had similar thoughts for cervical cancer 
(Figure 1). The majority rated these diseases as serious threats to their daughters’ health 
(HPV infection = 75%, cervical cancer = 92%).
HPV vaccine acceptability
Only 10% of parents had heard of HPV vaccine. However, after interviewers explained the 
purpose of the vaccine, the majority of parents (96%) said they would definitely get it for 
their daughters. Nearly all parents (98%) would definitely get the vaccine if a doctor 
recommended it. When asked who they would consult in the decision to vaccinate their 
daughter (respondents were allowed to provide more than one option), respondents said they 
would involve family members (82%), elders in their communities (14%), or their doctors 
(13%). Sixty-five percent of parents believed that getting HPV vaccine would increase their 
daughter’s likelihood of having sex.
Parents reported that the most common place they would take their daughters to get HPV 
vaccine was a public or community clinic (57%), followed by a primary care office (20%), 
and a school clinic (13%). The majority (87%) stated that they would get the vaccine for 
their daughters if it were offered at their schools. The most common barriers that parents 
listed for getting HPV vaccine were cost (52%), transportation (23%), family responsibilities 
(19%), lack of awareness of places to procure the vaccine (17%), and availability of the 
vaccine (16%) (Figure 2). The median amount that parents said they would be willing to pay 
for HPV vaccine was 250 gourdes (US $4.65), which is higher than the country’s minimum 
wage (225 gourdes) for an eight-hour shift among garment workers.20
Discussion
In a sample of healthcare-seeking adults in Haiti, awareness of HPV was low. This finding is 
consistent with studies conducted in other Latin American and Caribbean countries, for 
example, cross-sectional studies in Trinidad, Honduras, and Brazil found HPV awareness 
ranging from 23% to 37%.21–23 In addition, the high level of HPV vaccine acceptability for 
daughters among our sample of healthcare-seeking parents (96%) was nearly identical to 
that found in a previous study of 485 women in rural Haiti (95%).9 High acceptability of 
HPV vaccine has been previously demonstrated across Latin American and Caribbean 
countries.22–25
Studies of HPV awareness among Haitian immigrants in the U.S. have reported a range in 
levels of awareness. On the high end of the spectrum, two studies conducted in the U.S. 
Northeast region reported levels of awareness close to and exceeding the 68% found in the 
general population of the U.S.26 For example, a study of young U.S.-born and immigrant 
Haitian women found that 72% were aware of HPV.10 Similarly, a study of Haitian 
immigrant mothers of 11–17 year old daughters reported that 65% had heard of HPV.11 In 
contrast, a community based sample in Little Haiti, a predominantly Haitian neighborhood 
in Miami, Florida, found that only 22% were aware of HPV12 which is similar to that found 
in our sample. The variation in awareness in these different populations indicate that U.S. 
samples may not be an appropriate proxy. Depending on geographic location and healthcare 
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access, Haitian immigrants in the U.S. may be exposed to different levels of information 
about HPV.
Contrary to studies conducted in other Latin American and Caribbean countries, we did not 
find differences in HPV awareness based on socioeconomic factors such as education level 
or employment status. In a study conducted in Trinidad, adult women with secondary 
education and above were more likely to be aware of HPV.21 Research conducted in both 
Brazil and the Bahamas, found that awareness was associated with higher education and 
income.21, 27 Rather, we found that respondents with a history of STIs and those who were 
aware of genital warts, a disease caused by HPV, were more likely to be aware of HPV. This 
could indicate that healthcare providers may be primarily giving information about HPV to 
patients that are already diagnosed with a STI or those considered to be at high-risk for such 
an infection. Considering the high prevalence of carcinogenic strains of HPV in Haiti (19% 
of adult Haitian women have oncogenic HPV infection),28 information should be distributed 
to all adolescents and young adults, not based on risk.
Currently, HPV vaccine is offered in Haiti in limited quantities through non-governmental 
organization (e.g., Gavi Alliance)7 and industry (e.g., Gardasil Access Program) 
donations.29 However, a coordinated national program of HPV vaccine administration does 
not exist in Haiti. In June 2014, Family Health Ministries, a non-profit corporation which 
provides healthcare and education services in Haiti, held discussions with senior officials at 
the Haitian Ministry of Health to discuss national priorities around HPV vaccination. 
Officials noted that in light of the urgency to increase widespread coverage of childhood 
vaccinations like Tdap and polio, HPV vaccination was a lower priority. While private 
clinics may import the vaccine independent of government-sponsorship for administration to 
patients willing to pay, there is no data available to assess the prevalence of this practice. In 
Latin American and Caribbean countries with high rates of communicable childhood 
diseases, health officials are often forced to make decisions about which vaccines to 
implement given vaccine costs and disease incidence.30 The burden of cost was echoed by 
participants in the study. Over half of the sample said that they anticipated cost to be their 
primary barrier to getting HPV vaccine were to become more widely available. The median 
amount participants said they would be willing to pay was $4.65. Given that the current 
price of HPV vaccine ranges from $4.50 per dose for low income countries and over $150 
per dose in high income countries,31 the necessary 2–3 doses8 of the vaccine would be out of 
reach for participants without government assistance.
In addition to cost, any effort to distribute HPV vaccine in Haiti should consider the 
locations that residents would most easily reached and use. The majority (57%) of 
participants said that the first place they would go to get the vaccine for their daughter would 
be a community clinic, and almost all (87%) said they would get the vaccine for their 
daughter at her school if it were offered there. A previous evaluation of school-located 
vaccination program in 7 schools in Haiti showed HPV vaccine uptake rates as high as 87% 
among girls 9–13 years old.29 School-located programs are a promising avenue for 
increasing HPV vaccination coverage, however, such programs may leave out the many girls 
who do not attend primary or secondary school. About 78% of girls attend primary school 
and only 29% attend secondary school in Haiti.32 A study of vaccination programs in 
Gichane et al. Page 6
J Pediatr Adolesc Gynecol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
multiple low-income countries found that those that included both school and clinic sites had 
higher coverage and higher rates of completion of the full 3 dose vaccine course.29 In Haiti, 
a hybrid approach would be critical due to the high proportion of adolescent girls that do not 
attend school.
Despite low awareness of HPV, almost all parents said that they would get HPV vaccine for 
their daughters if their doctor recommended it. Studies in high income countries have 
demonstrated the power of provider recommendations on HPV vaccine uptake,33–35 thus 
provider recommendation should be a central part of any vaccine programs to be instituted 
in Haiti. Furthermore, parents responded that they would include spouses/partners, 
immediate and extended family members, and even elders in their decision to vaccinate their 
daughter. Having this wide range in decision makers means that HPV vaccine messages 
should be disseminated beyond clinical settings to reach family members and elders who 
may not be present at clinic appointments. Vaccination programs which have involved the 
community in following up with girls participating in the program have shown higher rates 
of HPV vaccine uptake,36 which signifies the importance of community education and 
positive social norms towards HPV vaccination.
Study limitations include our use of a cross-sectional design which limits our ability to infer 
causality to the associations we observed. The study’s convenience sample of healthcare-
seeking adults from two urban areas may have overestimated HPV awareness relative to the 
general population in Haiti as nearly half of adults in Haiti lack regular access to 
healthcare.37 Our sample was also of a higher socioeconomic status than the general 
population; a greater percentage of participants were employed (76% vs. 59% population)38 
and had more than a primary education (65% vs. 49% to 54% population).32 However, 
neither education or employment were significant predictors of HPV awareness in 
multivariate analyses which leads us to believe that this does not considerably hinder the 
generalizability of the results. Future studies will need to establish the generalizability of our 
findings to other adults in the general population. Additionally, hypothetical study of HPV 
vaccine acceptability may overestimate the interest in vaccination as programs are put in 
place, given barriers such as cost, transportation needs, and local health events related to 
vaccination.
The findings from this study have several implications for practice. First, approaches to 
increasing HPV awareness in Haiti should occur at the population level and not vary by 
socioeconomic status and risk level. In one of the study clinics, HPV and cervical cancer 
information is only provided to women before cervical cancer screening.39 This may be too 
late to prevent infection. An alternative strategy may be to provide HPV information to all 
patients at every clinical appointment. Second, given the high acceptability of the vaccine 
and the significant barrier of cost, the Haitian government should reconsider efforts towards 
applying for support from organizations that provide HPV vaccine at a reduced cost to low-
income countries. Haiti is one of the countries eligible for Gavi Alliance support due to its 
gross domestic product,7 and already receives funds from the organization for Hepatitis B, 
rotavirus, and pneumococcal vaccines.40 Finally, health education messaging about HPV 
and HPV vaccine should be designed to engage parents, family members, and community 
elders in order to ensure the highest level of vaccine uptake.
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In conclusion, our results provide unique information about HPV and HPV vaccine related 
attitudes in Haiti. Overall, awareness of HPV was low in a sample of healthcare-seeking 
adults. Health interventions should focus on increasing awareness of HPV. Moreover, as 
vaccination programs are introduced in Haiti, special attention should be taken in selecting 
vaccine distribution sites that are accessible, making the vaccine affordable, and ensuring 
messaging about HPV vaccine reaches a wide audience.
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Figure 1. 
Parents’ beliefs about HPV-related diseases (n=250).
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Figure 2. 
Parents’ perceived barriers to HPV vaccination (n=250)
Only parents of daughters answered this question. Participants could list up to 3 responses. 
Responses in the “other” category included daughter’s pregnancy, more pressing health 
concerns, and lack of confidence in vaccine efficacy.
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Table 1
Characteristics of respondents (n = 475).
Terre Noire Léogâne Overall
n (%) n (%) n (%)
Demographic characteristics
  Sex **
    Male N/A 65 (21) 65 (14)
    Female 160 (100) 250 (79) 410 (86)
  Age **
    18–39 y 67 (42) 232 (74) 299 (58)
    ≥ 40 y 93 (58) 83 (26) 176 (42)
  Marital status
    Not married 59 (37) 144 (46) 203 (43)
    Married or living together 101 (63) 171 (54) 272 (57)
  Education *
    Primary education or less 66 (41) 99 (31) 165 (35)
    More than primary education 94 (59) 216 (68) 310 (65)
  Employment status**
    Unemployed or student 17 (11) 98 (31) 115 (24)
    Employed 143 (89) 217 (69) 360 (76)
  Religious background**
    Catholic 24 (15) 91 (29) 115 (24)
    Other Christian/Protestant 128 (80) 200 (63) 328 (69)
    Other/ No religion 8 (5) 24 (8) 32 (7)
  Daughter in HPV vaccine age range**
    No female children 26 (16) 117 (37) 225 (47)
    Daughter outside of age range 25 (15) 57 (18) 103 (22)
    Daughter ages 11–26 109 (68) 141 (45) 147 (31)
Personal health & disease awareness
Had sexually transmitted infection
  No 133 (83) 295 (94) 428 (90)
  Yes 27 (17) 20 (6) 47 (10)
Contraceptive use
  No 105 (66) 269 (85) 374 (79)
  Yes 55 (34) 46 (15) 101 (21)
Heard of genital warts
  No 90 (56) 265 (84) 355 (75)
  Yes 70 (44) 50 (16) 120 (25)
Knew someone with cervical cancer
  No 116 (72) 201 (64) 317 (67)
  Yes 44 (28) 114 (36) 158 (33)
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N/A = Not applicable
*p<.05;
**p<.01
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Table 2
Correlates of human papillomavirus (HPV) awareness (n = 475).
No. respondents
aware of HPV/total
(%)
Bivariate OR
(95% CI)
Multivariable OR
(95% CI)
Overall 130/475 (27) N/A N/A
Demographic characteristics
Sex
  Male 11/65 (17) Ref --
  Female 119/410 (29) 2.00 (1.01–3.97)* --
Age
  18–39 y 63/299 (21) Ref --
  ≥ 40 y 67/176 (38) 2.30 (1.52–3.48)** --
Marital status
  Not married 80/272 (29) Ref --
  Married or living together 50/203 (25) 0.78 (0.52–1.18) --
Education
  Primary education or less 51/165 (31) Ref --
  More than primary education 79/310 (25) 0.76 (0.50–1.16) --
Employment status
  Unemployed or student 18/115 (16) Ref --
  Employed 112/360 (31) 2.43 (1.40–4.22)** --
Religious background
  Catholic 23/115 (20) Ref --
  Christian/Protestant 103/328 (31) 1.83 (1.10–3.06)* --
  Other 4/32 (13) 0.57 (0.18–1.79) --
Daughter in HPV vaccine age range
  No female children 44/225 (20) Ref --
  Daughter outside of age range 29/103 (28) 1.61 (0.94–2.77) --
  Daughter ages 11–26 57/147 (39) 2.61 (1.63–4.16)** --
Personal health & disease awareness
Had sexually transmitted infection
  No 106/428 (25) Ref Ref
  Yes 24/47 (51) 3.17 (1.72–5.85)** 2.38 (1.10–5.13)*
Contraceptive use
  No 97/374 (26) Ref --
  Yes 33/101 (33) 1.39 (0.86–2.23) --
Heard of genital warts
  No 62/ 355 (17) Ref Ref
  Yes 68/120 (57) 6.18 (3.93–9.72) 4.37 (2.59–7.38)**
Knew someone with cervical cancer
  No 83/317 (26) Ref --
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No. respondents
aware of HPV/total
(%)
Bivariate OR
(95% CI)
Multivariable OR
(95% CI)
  Yes 47/158 (30) 1.19 (0.78–1.82) --
Multivariate model contains all correlates significant (p < .05) in bivariate models adjusting for clinic site.
OR = Odds ratio; CI = confidence interval; Ref = Referent group; N/A = Not applicable.
*p<.05;
**p<.01
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